StreetAlpha
13F holdings · Q3 2026

Acuta Capital Partners

Redwood City, CA · files as Acuta Capital Partners, LLC
Know the moment Acuta Capital Partners filesYou follow Acuta Capital Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1582844

Acuta Capital Partners reported 34 stocks worth $130M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (18.9%), WHWK (13.6%) and TNGX (7.9%). Compared with Q2 2026, the fund opened new positions in VOGX, SLN and IRD, added to PRAX, TNGX and FDMT and trimmed AVBP, SRZN and AVLN.

Latest filing: what Acuta Capital Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
11 new12 added8 trimmed0 sold outBought about $23.8M · sold about $14.5M
New 11
See all 11 →
Added 12
See all 12 →
Trimmed 8
See all 8 →
Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$130M−9.7% vs last quarter · $132M including options
Stocks held3411 new · 0 sold out
Top 5 weight50.4%fairly concentrated
Turnover30%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PRAX
Praxis Precision Medicines I
$24.5M18.9%84K+1,397 (+2%)8 of 8
2
WHWK
Whitehawk Therapeutics Inc
$17.6M13.6%4.7MNo change8 of 8
3
TNGX
Tango Therapeutics Inc
$10.2M7.9%410K+19K (+5%)4 of 8
4
FDMT
4D Molecular Therapeutics in
$7.7M5.9%535K+27K (+5%)2 of 8
5
ARGX
Argenx SE
$5.3M4.1%5,558+853 (+18%)8 of 8
6
AVBP
Arrivent Biopharma Inc
$5.2M4.0%171K−48K (−22%)2 of 8
7
SRZN
Surrozen Inc
$4.9M3.8%153K−21K (−12%)7 of 8
8
VOGX
Vogenx Inc
$4.9M3.8%213KNew position1 of 8
9
DRUG
Bright Minds Biosciences Inc
$4.6M3.6%93K+407 (+0%)8 of 8
10
OCUL
Ocular Therapeutix Inc
$4.4M3.4%575K+42K (+8%)8 of 8
🔒 24 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Options

valued at the underlying shares
StockTypeValueSharesChange
ACAD
Acadia Pharmaceuticals Inc
Call$2M1,000+1,000

Reported value

last 8 quarters
$99.4MQ4 '24
$86.2MQ1 '25
$71.6MQ2 '25
$96.8MQ3 '25
$147MQ4 '25
$141MQ1 '26
$143MQ2 '26
$130MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Acuta Capital Partners 13F FAQ

What does Acuta Capital Partners own?

Acuta Capital Partners reported 34 stocks worth $130M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (18.9%), WHWK (13.6%) and TNGX (7.9%). The table above lists every position in the filing (the top 10 without an account).

What did Acuta Capital Partners buy and sell in Q3 2026?

Compared with Q2 2026: 11 new positions, 12 added to, 8 trimmed and 0 sold out. New positions include VOGX, SLN and IRD.

When will Acuta Capital Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Acuta Capital Partners's portfolio worth?

The Q3 2026 filing reports $130M in US stocks ($132M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.